|
|
Volumn 54, Issue 7, 2015, Pages 532-534
|
|
Translating Pharmacogenetics to Clinical Practice: Do Cytochrome P450 2D6 Ultrarapid Metabolizers Need Higher Atomoxetine Doses?
a,b,c
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ATOMOXETINE;
CYTOCHROME P450 2D6;
FLUOXETINE;
PAROXETINE;
RISPERIDONE;
ARTICLE;
CLINICAL PRACTICE;
DRUG INDUSTRY;
FOOD AND DRUG ADMINISTRATION;
GENETIC SCREENING;
GENOTYPE;
HUMAN;
HUMAN GENOME;
PERSONALIZED MEDICINE;
PHARMACOGENETICS;
PRESCRIPTION;
PRIORITY JOURNAL;
GENETICS;
METABOLISM;
PRACTICE GUIDELINE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
UNITED STATES;
ATOMOXETINE HYDROCHLORIDE;
CYTOCHROME P-450 CYP2D6;
HUMANS;
PHARMACOGENETICS;
PRACTICE GUIDELINES AS TOPIC;
PRECISION MEDICINE;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84931059701
PISSN: 08908567
EISSN: 15275418
Source Type: Journal
DOI: 10.1016/j.jaac.2015.04.003 Document Type: Editorial |
|
Times cited : (14)
|
|
References (5)
|
